Evaluation of 2-(4-Chlorophenyl)-4-(4-Fluorophenyl)-5-Pyridin-4-Yl-1,2-Dihydropyrazol-3-One As a p38 MAPK Inhibitor in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines. AJPS 2025, 25 (3), 317-326. https://doi.org/10.32947/ajps.v25i3.1224.